Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221357 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
A Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 990
- Enrollment target
- 20
- Study locations
NCT07221357 is a Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 990 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT07221357, a Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 990 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Pumitamig
- DRUG FOLFIRI
- DRUG FOLFOX
- DRUG CAPOX
Study Locations (20)
California
- Local Institution - 0263 - Los Angeles
- Local Institution - 0345 - Orange
- Local Institution - 0317 - San Francisco
- Local Institution - 0330 - Santa Monica
- Local Institution - 0293 - Stanford
Florida
- Florida Cancer Specialists - East - Cape Coral
- Florida Cancer Specialists - North - St. Petersburg
- Local Institution - 0269 - Tampa
Georgia
- Local Institution - 0276 - Duluth
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Illinois
- Local Institution - 0030 - Chicago
- Local Institution - 0433 - Chicago
Maryland
- Local Institution - 0262 - Baltimore
- Maryland Oncology Hematology - Silver Spring - Silver Spring
Michigan
- Local Institution - 0430 - Ann Arbor
- Local Institution - 0254 - Grand Rapids
Arkansas
- Local Institution - 0432 - Springdale
Iowa
- Local Institution - 0335 - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2025-12-31 |
| Est. Completion | 2034-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221357
The ClinicalTrials.gov registry entry for NCT07221357 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 990 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Untreated, Unresectable, or Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07221357 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07221357 about?
NCT07221357 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer". The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
What is the current status of trial NCT07221357?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 990 participants. The study started on 2025-12-31. Estimated completion is 2034-03-11.
What conditions does trial NCT07221357 study?
This clinical trial studies the following conditions: Untreated, Unresectable, or Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT07221357?
The interventions under investigation include: Bevacizumab (DRUG), Pumitamig (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), CAPOX (DRUG).
Who is sponsoring clinical trial NCT07221357?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221357 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.